| Thursday 8 March
|
|
07:15 08:00
|
|
Clinical Expert 3: How should we screen for Cushing's syndrome?
Hall 9
Chair: J Newell-Price (Sheffield)
B Atkinson (Belfast)
|
| |
|
|
|
07:15 08:00
|
|
Clinical Expert 4: Erectile dysfunction and androgens
Genourously supported by Ipsen Ltd
Hall 11
Chair: N Hanley (Southampton)
P Bouloux (London)
|
| |
|
|
|
08:15 08:50
|
|
Society for Endocrinology Medal Lecture
What happens to cortisol in obesity and metabolic syndrome, what effect does cortisol have on the outcomes of cardiovascular disease, and is inhibition of 11beta-HSD1 the answer?
Hall 1
Chair: J Buckingham (London)
|
|
S7
|
Cortisol and cardiovascular disease: from cradle to grave
B Walker ( (Edinburgh))
|
| |
|
|
|
08:55 09:30
|
|
Clinical Endocrinology Trust Lecture
There is increasing awareness that defective intracellular trafficking of molecules leads to disease. This is illustrated by recent findings in ACTH insensitivity syndromes causing adrenal insufficiency
Hall 1
Chair: L Rees (London)
|
|
S8
|
Failing to stop, failing to signal, no insurance, and other trafficking defects in the adrenal
A Clark ( (London))
|
| |
|
|
|
09:30 10:00
|
|
Coffee
Hall 3
|
| |
|
|
|
10:00 12:00
|
|
Clinical Management Workshop 3: New aspects of phaeochromocytoma
New genetic syndromes have changed the management of patients with sporadic phaeocromocytoma
Supported by Clinical Endocrinology
Hall 1
Chairs: J Connell (Glasgow) & M Brown (Cambridge)
|
| 10:00 |
S53
|
Familial phaeochromocytoma syndromes
E Maher ( (Birmingham))
|
| 10:30 |
S54
|
New Aspects of phaeochromocytoma: managing young people with phaeochromocytoma
S Ball ( (Newcastle upon Tyne))
|
| 11:00 |
S55
|
Biochemical testing - which test in which patient
R Peaston ( (Newcastle upon Tyne))
|
| 11:30 |
S56
|
Clinical case discussion
S Ritchie (Glasgow)
|
| |
|
|
|
10:00 11:30
|
|
Clinical Management Workshop 4: Differentiated thyroid cancer
An overview of the ideal sugical approach to thyroid cancer
Supported by Clinical Endocrinology
Hall 11
Chairs: J Lazarus (Cardiff) & M Strachan (Edinburgh)
|
| 10:00 |
S57
|
Clinical management of thyroid cancer: new guidelines
P Perros ( (Newcastle upon Tyne))
|
| 10:30 |
S58
|
Surgical management of differentiated thyroid cancer
B Harrison ( (Sheffiled))
|
| 11:00 |
S59
|
An update in the management practices of thyroid cancer and the use of rhTSH
M Schlumberger ( (Villejuif, France))
|
| |
|
|
|
12:00 12:45
|
|
Clinical Expert 5: Endocrine hypertension
Hall 9
Chair: P Stewart (Birmingham)
M Brown (Cambridge)
|
| |
|
|
|
12:00 12:45
|
|
Clinical Expert 6: New developments in risk reduction in diabetes
Hall 11
Chair: M Gibson (Manchester)
TBC
|
| |
|
|
|
12:45 13:15
|
|
Lunch and posters
Hall 3
|
| |
|
|
|
13:15 15:15
|
|
Symposium 8: Aspects of cardiovascular risk management in diabetes
New approaches to the management of cardiovascular risk in diabetes are urgently required. This symposium will address new therapeutic targets in metabolic syndrome and in type 1 and type 2 diabetes.
Genourously supported by AstraZeneca Plc
Hall 1
Chairs: P Durrington (Manchester) & J Petrie (Dundee)
|
| 13:15 |
S37
|
The value of PPAR agonists in relation to endothelial function
J Petrie (Dundee)
|
| 13:45 |
S38
|
Developments in the dyslipidaemia of diabetes
C Packard ( (Glasgow))
|
| 14:15 |
S39
|
Cardiovascular risk and risk management in type 1 diabetes
N Chaturvedi ( (London))
|
| 14:45 |
S40
|
Aldosterone Induced Vascular Inflammatory Disease: Mechanisms and Implications for Clinical Practice
R Rocha ( (Novartis Pharmaceuticals))
|
| |
|
|
|
13:15 14:45
|
|
Symposium 9: New biology of bone: therapeutic implications
Recently, serveral new insights have been gained into the signalling between bone cells. These discoveries have now been translated into novel treatments for bone diseases, especially osteophorosis. This symposium explores this new understanding of bone physiology and how the lessons learned can be translated into clinical practice.
Genorously supported by Amgen
Hall 11
Chairs: M Cooper (Birmingham) & P Selby (Manchester)
|
| 13:15 |
S41
|
LRP5
A Koay (GE Healthcare)
|
| 13:45 |
S42
|
Osteoclast differentiation and function
T Chambers ( (London))
|
| 14:15 |
S43
|
Rank Modulation in Treatment
M McClung ( (Portland, USA))
|
| 14:45 |
S44
|
Emerging new targets for home therapy. Cathespsins, WNTs, calcilytics and other approaches
G Russell (Oxford)
|
| |
|
|